Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2016 (2016), Article ID 1426279, 7 pages
http://dx.doi.org/10.1155/2016/1426279
Review Article

An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration for a Novel Pharmaceutical Class

1Markle & Hinshaw Gynecology and Harris Regional Hospital, 7190 Ellijay Road, Franklin, NC 28734, USA
2Eli Lilly and The Indiana EPA, 10113 Partridge Place, Carmel, IN 56033, USA

Received 28 August 2016; Accepted 15 September 2016

Academic Editor: George P. Lyritis

Copyright © 2016 W. Banks Hinshaw and Allyn F. DeLong. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Shane, D. Burr, P. R. Ebeling et al., “Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research,” Journal of Bone and Mineral Research, vol. 25, no. 11, pp. 2267–2294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Shane, D. Burr, B. Abrahamsen et al., “Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research,” Journal of Bone and Mineral Research, vol. 29, no. 1, pp. 1–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. T. L. N. Järvinen, K. Michaëlsson, J. J. Collins et al., “Overdiagnosis of bone fragility in the quest to prevent hip fracture,” The British Medical Journal, vol. 350, Article ID h2088, 2015. View at Google Scholar
  4. I. R. Orriss, T. R. Arnett, and R. G. G. Russell, “Pyrophosphate: a key inhibitor of mineralisation,” Current Opinion in Pharmacology, vol. 28, pp. 57–68, 2016. View at Publisher · View at Google Scholar
  5. J. J. Reynolds, C. Minkin, D. B. Morgan, D. Spycher, and H. Fleisch, “The effect of two diphosphonates on the resorption of mouse calvaria in vitro,” Calcified Tissue Research, vol. 10, no. 1, pp. 302–313, 1972. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Delong, J. Feinblatt, and H. Rasmussen, “The effect of pyrophosphate infusion on the response of the thyroparathyroidectomized rat to parathyroid hormone and adenosine-3′,5′-cyclic monophosphate,” Calcified Tissue Research, vol. 8, no. 1, pp. 87–95, 1971. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Fleisch, “Development of bisphosphonates,” Breast Cancer Research, vol. 4, no. 1, pp. 30–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Fleish and W. F. Neuman, “Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase,” The American Journal of Physiology, vol. 200, no. 6, pp. 1296–1300, 1961. View at Google Scholar · View at Scopus
  9. B. S. Strates, W. F. Neuman, and G. J. Levinskas, “The solubility of bone mineral. II. Precipitation of near-neutral solutions of calcium and phosphate,” The Journal of Physical Chemistry, vol. 61, no. 3, pp. 279–282, 1957. View at Publisher · View at Google Scholar · View at Scopus
  10. C. C. Solomons and W. F. Neuman, “On the mechanisms of calcification: the remineralization of dentin,” The Journal of Biological Chemistry, vol. 235, no. 8, pp. 2502–2506, 1960. View at Google Scholar · View at Scopus
  11. H. Fleisch and S. Bisaz, “Isolation from urine of pyrophosphate, a calcification inhibitor,” The American Journal of Physiology, vol. 203, no. 10, pp. 671–675, 1962. View at Google Scholar · View at Scopus
  12. H. Fleisch, R. G. G. Russell, and F. Straumann, “Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis,” Nature, vol. 212, no. 5065, pp. 901–903, 1966. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Fleisch, F. Straumann, R. Schenk, S. Bisaz, and M. Allgöwer, “Effect of condensed phosphates on calcification of chick embryo femurs in tissue culture,” American Journal of Physiology, vol. 211, no. 3, pp. 821–825, 1966. View at Google Scholar · View at Scopus
  14. H. Fleisch, R. G. G. Russell, S. Bisaz, P. A. Casey, and R. C. Mühlbauer, “The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo,” Calcified Tissue Research, vol. 2, no. 1, p. 10, 1968. View at Publisher · View at Google Scholar · View at Scopus
  15. R. G. G. Russell, R. C. Mühlbauer, S. Bisaz, D. A. Williams, and H. Fleisch, “The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats,” Calcified Tissue Research, vol. 6, no. 1, pp. 183–196, 1970. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Francis, “The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates,” Calcified Tissue Research, vol. 3, no. 1, pp. 151–162, 1969. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Jung, R. G. Russel, S. Bisaz, D. B. Morgan, and H. Fleisch, “Fate of intravenously injected pyrophosphate-32P in dogs,” The American Journal of Physiology, vol. 218, no. 6, pp. 1757–1764, 1970. View at Google Scholar · View at Scopus
  18. C. W. Cooper, C. W. Yates Jr., and R. V. Talmage, “Some endogenous parathyroid hormone effects manifested by bone in vitro,” Experimental Biology and Medicine, vol. 119, no. 1, pp. 81–88, 1965. View at Publisher · View at Google Scholar · View at Scopus
  19. R. G. G. Russell and H. Fleisch, “Pyrophosphate and diphosphonates in skeletal metabolism,” Clinical Orthopaedics and Related Research, vol. 108, no. 1, pp. 241–263, 1975. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Jung, S. Bisaz, and H. Fleisch, “The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals,” Calcified Tissue Research, vol. 11, no. 4, pp. 269–280, 1973. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Mukherjee, Y. Song, and E. Oldfield, “NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model,” Journal of the American Chemical Society, vol. 130, no. 4, pp. 1264–1273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Rasmussen, C. Anast, C. Arnold, and A. DeLong, “Regulation of bone in cell function,” in Osteoporosis, U. S. Barzel, Ed., pp. 187–198, Grune and Stratton Inc, New York, NY, USA, 1970. View at Google Scholar
  23. C. Anast, C. D. Arnaud, H. Rasmussen, and A. Tenenhouse, “Thyrocalcitonin and the response to parathyroid hormone,” The Journal of Clinical Investigation, vol. 46, no. 1, pp. 57–64, 1967. View at Publisher · View at Google Scholar · View at Scopus
  24. H. F. Kohler and M. M. Pechet, “The inhibition of bone resorption by thyrocalcitonin,” Journal of Clinical Investigation, vol. 45, no. 6, p. 1033, 1967. View at Google Scholar
  25. J. Blaine, M. Chonchol, and M. Levi, “Renal control of calcium, phosphate, and magnesium homeostasis,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 7, pp. 1257–1272, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Orimo, T. Fujita, and M. Yoshikawa, “Pyrophosphate enhancement of hypocalcemic effect of thyrocalcitonin in rat,” Endocrinologia Japonica, vol. 16, no. 3, pp. 309–313, 1969. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Orimo, T. Fujita, and M. Yoshikawa, “Pyrophosphate enhancement of thyrocalcitonin effect in tissue culture,” Endocrinologia Japonica, vol. 16, no. 4, pp. 415–421, 1969. View at Publisher · View at Google Scholar · View at Scopus
  28. D. H. Copp, “Calcitonin: discovery, development, and clinical application,” Clinical and Investigative Medicine, vol. 17, no. 3, pp. 268–277, 1994. View at Google Scholar · View at Scopus
  29. R. G. G. Russell, S. Bisaz, A. Donath, D. B. Morgan, and H. Fleisch, “Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone,” The Journal of Clinical Investigation, vol. 50, no. 5, pp. 961–969, 1971. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Fraser, “Hypophosphatasia,” The American Journal of Medicine, vol. 22, no. 5, pp. 730–746, 1957. View at Publisher · View at Google Scholar · View at Scopus
  31. J. D. Coe, W. A. Murphy, and M. P. Whyte, “Management of femoral fractures and pseudofractures in adult hypophosphatasia,” The Journal of Bone & Joint Surgery—American Volume, vol. 68, no. 7, pp. 981–990, 1986. View at Google Scholar · View at Scopus
  32. M. P. Whyte, “Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia,” Journal of Bone and Mineral Research, vol. 24, no. 6, pp. 1132–1134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. R. A. L. Sutton, S. Mumm, S. P. Coburn, K. L. Ericson, and M. P. Whyte, “‘Atypical femoral fractures’ during bisphosphonate exposure in adult hypophosphatasia,” Journal of Bone and Mineral Research, vol. 27, no. 5, pp. 987–994, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Bhattacharyya, S. Jha, H. Wang, D. L. Kastner, and E. F. Remmers, “Hypophosphatasia and the risk of atypical femur fractures: A Case—Control Study,” BMC Musculoskeletal Disorders, vol. 17, no. 1, pp. 332–335, 2016. View at Publisher · View at Google Scholar
  35. C. C. Solomons and J. Styner, “Osteogenesis imperfecta: effect of magnesium administration on pyrophosphate metabolism,” Calcified Tissue Research, vol. 3, no. 1, pp. 318–326, 1969. View at Publisher · View at Google Scholar · View at Scopus
  36. J. L. Granda, K. A. Falvo, and P. G. Bullough, “Pyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta,” Clinical Orthopaedics and Related Research, vol. 126, pp. 228–231, 1977. View at Google Scholar · View at Scopus
  37. W. E. Hathaway, C. C. Solomons, and J. E. Ott, “Platelet function and pyrophosphates in osteogenesis imperfecta,” Blood, vol. 39, no. 4, pp. 500–509, 1972. View at Google Scholar · View at Scopus
  38. E. Brizola and J. R. Shapiro, “Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions,” Calcified Tissue International, vol. 97, no. 2, pp. 101–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Hegazy, M. Kenawey, E. Sochett, L. Tile, A. M. Cheung, and A. W. Howard, “Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy,” Journal of Pediatric Orthopaedics, vol. 36, no. 7, pp. 757–761, 2016. View at Google Scholar
  40. J. D. Robinson, R. K. Leighton, K. Trask, Y. Bogdan, and P. Tornetta, “Periprosthetic atypical femoral fractures in patients on long-term bisphosphonates: a multicenter retrospective review,” Journal of Orthopedic Trauma, vol. 30, no. 4, pp. 170–176, 2016. View at Publisher · View at Google Scholar
  41. W. S. Dearden, “Fragilitas ossium amongst workers in lucifer match factories,” The British Medical Journal, vol. 29, pp. 270–271, 1899. View at Google Scholar
  42. W. S. Dearden, “The causation of phosphorus necrosis,” British Medical Journal, pp. 408–410, 1901. View at Google Scholar
  43. T. E. Thorpe, T. Oliver, and G. Cunningham, Reports to the Secretary of State for the Home Department on the Use of Phosphorus in the Manufacture of Lucifer Matches, Eyre and Spottiswoode, London, UK, 1899, http://victoria.cdlr.strath.ac.uk/display.php?id=SAFH.
  44. W. B. Hinshaw and L. D. Quin, “Recognition of the causative agent of ‘phossy jaw’ and ‘fragile femur’ in fumes arising from white phosphorus,” Journal of Phosphorus Sulfur Silicon and the Related Elements, vol. 190, no. 12, pp. 2082–2093, 2015. View at Google Scholar
  45. A. Hamilton, “Chronic phosphorus poisoning,” in Diseases of Occupation and Vocational Hygiene, G. M. Kober and W. C. Hanson, Eds., pp. 145–152, P Blakiston's Son & Co, Philadelphia, Pa, USA, 1916. View at Google Scholar
  46. L. Gedmintas, D. H. Solomon, and S. C. Kim, “Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis,” Journal of Bone and Mineral Research, vol. 28, no. 8, pp. 1729–1737, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. J. Spanggord, R. Rewick, -W. Chou et al., “Environmental Fate of White Phosphorus/Felt and Red Phosphorus/Butyl Rubber Military Screening Smokes,” U.S. Army Medical Research and Development Command, ID #DAMD17-82-C-2320, pp 68-69, 1985.
  48. M. A. Karsdal, P. Qvist, C. Christiansen, and L. B. Tankó, “Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?” Drugs, vol. 66, no. 15, pp. 1909–1918, 2006. View at Publisher · View at Google Scholar · View at Scopus